S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.57
+1.89
+11.33%
NUWE · Nuwellis, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
$0.54
-0.01
(-2.19%)
● At close: October 21 at 4:00:00 PM EDT
$0.52
-0.00
(-0.31%)
Pre-Market:
5:28:43 AM EDT
DAY'S RANGE
$0.54
$0.54
$0.55
52-WEEK RANGE
$0.54
$0.44
$172.90
What's happening
- NUWE is down 2.19% today, trading at $0.54. — Live quote
- It's trading within 3% of its 52-week low ($0.44). (Finnhub fundamentals)
- Volume today (1,800) is well below its 3-month average of 3,132,170. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-26.64 actual vs. $-0.69 estimated (-3740.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 0
Buy 0
Hold 3
Sell 1
Strong sell 2
Aggregate ratings for 2026-10-01 (6 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
NUWE
-99.10%
vs S&P 500
-111.87%
1-YEAR RETURN
NUWE
-99.55%
vs S&P 500
-114.11%
6-MONTH RETURN
NUWE
-98.68%
3-MONTH RETURN
NUWE
-80.72%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-26.64
Est. $-0.69
MISS -3740.8%
2026-04-26 (Q1 2026)
$-73.15
Est. $-35.70
MISS -104.9%
2026-01-26 (Q4 2025)
$-52.50
Est. $-55.69
BEAT +5.7%
2025-04-26 (Q1 2025)
$-1014.30
Est. $-1139.54
BEAT +11.0%
Valuation Measures & Ratios
Enterprise Value4-$2.0M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)0.21
Price / Book71.04
EV4 / Revenue-0.22
EV4 / EBITDA—
Profit Margin-125.63%
Operating Margin-142.87%
Return on Equity (ROE8)-211.49%
Return on Assets (ROA9)-150.03%
Avg Volume (3M)3,132,170
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $555.5K | $76.2M | $94.5M | $1.9M | $147.0M |
| P/E | -0.03 | -3.88 | -7.42 | -0.09 | -11.57 |
| Price/Sales | 0.07 | 9.24 | 11.50 | 0.23 | 17.67 |
| Price/Book | -0.27 | 28.64 | 24.18 | -0.21 | 41.09 |
| EV/Revenue | -0.40 | 8.99 | 11.13 | -0.31 | 17.36 |
| ROE | 1043.99% | -738.07% | -326.02% | 233.64% | -355.25% |
| ROA | -235.09% | -282.14% | -159.58% | -227.54% | -181.43% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short167,440
Change from Prior Settlement+339.57%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 14.1% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-08-26; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -125.6%. Finnhub fundamentals ↗
- Trailing 52-week price return is -99.5%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on NUWE
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $2.4M | $2.2M | $1.7M | $1.9M | $2.4M | $2.2M | $1.9M |
| Gross profit | $1.5M | $1.7M | $1.4M | $958.0K | $1.1M | $1.7M | $1.5M | $1.2M |
| Operating income | -$3.2M | -$4.6M | -$2.7M | -$2.9M | -$3.1M | -$1.5M | -$2.3M | -$4.7M |
| Net income | -$4.8M | -$4.5M | $468.0K | -$12.6M | -$3.0M | $2.4M | -$7.7M | -$4.3M |
| EPS (diluted) | $-26.64 | $-2.19 | $0.56 | $-2134.19 | $-28.93 | $73.23 | $-791.82 | $-24.11 |
| EPS (basic) | $-26.64 | $-2.19 | $0.56 | $-2134.19 | $-28.93 | $73.23 | $-791.82 | $-24.11 |
| Operating margin | -$161 | -$190 | -$122 | -$168 | -$161 | -$65 | -$106 | -$256 |
| Net margin | -$245 | -$189 | $21 | -$728 | -$158 | $100 | -$352 | -$233 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $9.1M | $7.0M | $6.1M | $8.0M | $9.2M | $7.0M | $9.9M | $6.7M |
| Total liabilities | $11.2M | $4.3M | $3.5M | $4.1M | $18.2M | $3.4M | $3.3M | $3.5M |
| Stockholders' equity | -$2.1M | $2.7M | $2.6M | $3.9M | -$9.0M | $3.6M | $6.5M | $3.2M |
| Total current assets | $7.9M | $5.8M | $5.2M | $7.2M | $8.4M | $6.1M | $8.9M | $5.5M |
| Total current liabilities | $4.0M | $3.7M | $3.0M | $3.5M | $3.9M | $2.7M | $2.6M | $2.7M |
| Cash & equivalents | $3.9M | $2.1M | $1.1M | $3.1M | $4.5M | $2.6M | $5.1M | $1.9M |
| Accounts receivable | $1.5M | $1.6M | $1.5M | $1.1M | $1.2M | $1.5M | $1.7M | $1.3M |
| Inventory | $1.7M | $1.8M | $1.9M | $2.2M | $2.0M | $1.8M | $1.7M | $1.9M |
| Other current assets | $690.0K | $406.0K | $698.0K | $776.0K | $745.0K | $274.0K | $315.0K | $430.0K |
| Property, plant & equipment | $347.0K | $365.0K | $368.0K | $414.0K | $359.0K | $405.0K | $478.0K | $551.0K |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | $102.0K | $112.0K | $0 | — | — | — | — | — |
| Other non-current assets | $599.0K | $420.0K | $271.0K | $21.0K | $21.0K | $21.0K | $21.0K | $120.0K |
| Accounts payable | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | $68.0K | $71.0K | $85.0K | $76.0K | $74.0K | $86.0K | $41.0K | $50.0K |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Retained earnings | -$325.7M | -$320.9M | -$316.3M | -$313.9M | -$314.4M | -$301.8M | -$298.8M | -$297.3M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.2M | -$3.1M | -$3.0M | -$3.1M | -$2.1M | -$2.5M | -$1.5M | -$2.5M |
| Investing cash flow | -$9.0K | -$284.0K | $12.0K | -$98.0K | -$4.0K | $0 | -$23.0K | $16.0K |
| Financing cash flow | $5.0M | $4.4M | $1.1M | $1.9M | $4.0M | $0 | $4.7M | $3.3M |
| Free cash flow | -$3.2M | -$3.1M | -$3.0M | -$3.2M | -$2.1M | -$2.5M | -$1.5M | -$2.5M |
| Capital expenditures | $9.0K | $30.0K | -$12.0K | $98.0K | $4.0K | $0 | $23.0K | -$16.0K |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $22.0K | $25.0K | $24.0K | $19.0K | $17.0K | $67.0K | $104.0K | $101.0K |
| Change in accounts receivable | -$14.0K | $66.0K | $352.0K | -$52.0K | -$347.0K | -$187.0K | $434.0K | $1.0K |
| Change in inventory | -$37.0K | -$181.0K | -$279.0K | $161.0K | $276.0K | $34.0K | -$159.0K | -$90.0K |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Sales/maturities of investments | — | — | — | — | — | — | $0 | $0 |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $8.3M | $8.7M | $8.9M | $8.5M | $7.9M |
| Gross profit | $5.1M | $5.7M | $5.0M | $4.8M | $4.5M |
| Operating income | -$11.1M | -$11.0M | -$17.6M | -$17.2M | -$19.5M |
| Net income | -$17.5M | -$11.2M | -$20.2M | -$14.5M | -$19.6M |
| EPS (diluted) | $-25.39 | $-353.30 | $-360.06 | $-83.55 | $-285.36 |
| EPS (basic) | $-25.39 | $-353.30 | $-360.06 | $-83.55 | $-285.36 |
| Operating margin | -$134 | -$126 | -$199 | -$201 | -$247 |
| Net margin | -$212 | -$128 | -$228 | -$170 | -$247 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $6.1M | $9.9M | $9.8M | $24.7M | $30.4M |
| Total liabilities | $3.5M | $3.3M | $6.6M | $12.3M | $4.5M |
| Stockholders' equity | $2.6M | $6.5M | $3.0M | $12.4M | $25.9M |
| Total current assets | $5.2M | $8.9M | $8.2M | $22.8M | $28.1M |
| Total current liabilities | $3.0M | $2.6M | $3.2M | $4.7M | $3.3M |
| Cash & equivalents | $1.1M | $5.1M | $3.8M | $17.7M | $8.7M |
| Accounts receivable | $1.5M | $1.7M | $2.0M | $1.4M | $750.0K |
| Inventory | $1.9M | $1.7M | $2.0M | $2.7M | $2.8M |
| Other current assets | $698.0K | $315.0K | $461.0K | $396.0K | $328.0K |
| Property, plant & equipment | $368.0K | $478.0K | $728.0K | $980.0K | $1.2M |
| Goodwill | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Other non-current assets | $271.0K | $21.0K | $120.0K | $21.0K | $21.0K |
| Accounts payable | — | — | — | — | $1.4M |
| Short-term debt | — | — | — | — | — |
| Other current liabilities | $85.0K | $41.0K | $51.0K | $58.0K | $36.0K |
| Long-term debt | — | — | — | — | — |
| Other non-current liabilities | — | — | — | $0 | $179.0K |
| Common stock & paid-in capital | $0 | $0 | $0 | $0 | $0 |
| Retained earnings | -$316.3M | -$298.8M | -$287.6M | -$267.4M | -$252.9M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$10.8M | -$9.6M | -$17.9M | -$15.1M | -$17.8M |
| Investing cash flow | -$90.0K | -$60.0K | $330.0K | $14.7M | -$15.7M |
| Financing cash flow | $6.9M | $11.0M | $3.7M | $9.4M | $27.9M |
| Free cash flow | -$10.9M | -$9.7M | -$18.1M | -$15.3M | -$18.1M |
| Capital expenditures | $90.0K | $60.0K | $149.0K | $122.0K | $219.0K |
| Depreciation & amortization | — | — | — | $372.0K | $488.0K |
| Share-based compensation | $127.0K | $478.0K | $670.0K | $862.0K | $1.3M |
| Change in accounts receivable | -$234.0K | -$224.0K | $545.0K | $656.0K | -$155.0K |
| Change in inventory | $192.0K | -$279.0K | -$697.0K | -$140.0K | $143.0K |
| Purchases of investments | — | — | — | $0 | $18.9M |
| Sales/maturities of investments | — | $0 | $578.0K | $14.8M | $3.4M |
| Debt issued | — | — | — | — | — |
| Debt repaid | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding NUWE as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2023-03-15 to 2025-06-10
Recent transactions
- Most recent: ERB JOHN L (CEO and President) — Derivative conversion of 7,522 shares on 2025-06-10.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| ERB JOHN L | CEO and President | Derivative conversion | 2025-06-10 | 7,522 |
| Jaramillo Nestor Jr. | President and CEO | Open market purchase | 2023-03-15 | 4,098 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-06-10 | ERB JOHN L | CEO and President | Derivative conversion | 7,522 | $0.06 |
| 2025-06-09 | ERB JOHN L | CEO and President | Derivative conversion | 1,092,500 | $0.06 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 09:14 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-26 | 8-K | 2026-08-25 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-03 | 8-K | 2026-07-31 | View on SEC.gov → |
| 2026-07-24 | 8-K | 2026-07-24 | View on SEC.gov → |
| 2026-06-24 | 8-K | 2026-06-23 | View on SEC.gov → |
| 2026-06-18 | 8-K | 2026-06-16 | View on SEC.gov → |
| 2026-06-10 | 8-K | 2026-06-08 | View on SEC.gov → |
| 2026-05-15 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-12 | 8-K | 2026-05-12 | View on SEC.gov → |
| 2026-04-29 | 4 | 2026-04-28 | View on SEC.gov → |
| 2026-04-29 | 4 | 2026-04-28 | View on SEC.gov → |
Recent news
Headlines about NUWE (Nuwellis, Inc.). Links open the publisher — we don’t host full articles.
-
Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT System
Yahoo · 2026-10-08 -
Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences
Yahoo Finance · 2026-10-01 -
Nuwellis Reports 31 Aquadex Console Sales in 2026, Expanding Recurring Revenue Opportunity
Yahoo Finance · 2026-09-17 -
Nuwellis Reports Strong Aquadex Console Adoption, with 31 Aquadex SmartFlow Consoles Sold Year-to-Date, Meaningfully Expanding Recurring Revenue Opportunity
Yahoo Finance · 2026-09-17 -
Nuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory Affairs
Yahoo Finance · 2026-09-16 -
Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical
Yahoo Finance · 2026-08-25 -
Nuwellis Inc (NUWE) (Q2 2026) Earnings Call Highlights: Revenue Surges 14% and Installed Base ...
Yahoo Finance · 2026-08-13 -
Nuwellis, Inc. (NUWE) Q2 2026 Earnings Call Prepared Remarks Transcript
Seeking Alpha · 2026-08-13
No headlines in this category right now — try “All”.